Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lung Stereotactic Body Radiation Therapy Regional Nodal Failure Is Not Predicted by Tumor Size

Lung Stereotactic Body Radiation Therapy Regional Nodal Failure Is Not Predicted by Tumor Size ORIGINAL ARTICLE Lung Stereotactic Body Radiation Therapy: Regional  Nodal Failure Is Not Predicted by Tumor Size Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M. Woody, MD, Chandana A. Reddy, MS, and Gregory M. M. Videtic, MD, CM, FRCPC inoperable non–small-cell lung cancer (NSCLC) patients. Introduction: To examine regional nodal failure patterns with Local control (LC) rates with lung SBRT are excellent, with respect to lesion size in medically inoperable early-stage non–small 1,2 prospective series demonstrating 88% to 98% LC at 3 years. cell lung cancer (NSCLC) patients treated with definitive lung ste- These rates approximate surgical LC rates from lobectomy, reotactic body radiation therapy (SBRT). the standard of care in medically operable patients. Unlike Methods: Between 2004 and 2012, 342 medically inoperable early- surgically resected patients, those treated with SBRT do not stage NSCLC patients treated with definitive SBRT were identified typically undergo pathologic characterization of the lymph in our institutional review board–approved prospective registry. All nodes. Despite lower rates of invasive mediastinal staging, patients were treated on a Novalis/BrainLAB system using ExacTrac retrospective SBRT series report either similar or lesser rates for image guidance. Kaplan–Meier analysis was performed with the of regional nodal failure compared with lobectomy patients. log-rank test used to detect differences between lesion size and nodal http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Lung Stereotactic Body Radiation Therapy Regional Nodal Failure Is Not Predicted by Tumor Size

Videtic, Gregory M. M.
Journal of Thoracic Oncology , Volume 9 (11) – Nov 1, 2014
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/lung-stereotactic-body-radiation-therapy-regional-nodal-failure-is-not-ViUHPcagM5

References (16)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000313
pmid
25185531
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Lung Stereotactic Body Radiation Therapy: Regional  Nodal Failure Is Not Predicted by Tumor Size Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M. Woody, MD, Chandana A. Reddy, MS, and Gregory M. M. Videtic, MD, CM, FRCPC inoperable non–small-cell lung cancer (NSCLC) patients. Introduction: To examine regional nodal failure patterns with Local control (LC) rates with lung SBRT are excellent, with respect to lesion size in medically inoperable early-stage non–small 1,2 prospective series demonstrating 88% to 98% LC at 3 years. cell lung cancer (NSCLC) patients treated with definitive lung ste- These rates approximate surgical LC rates from lobectomy, reotactic body radiation therapy (SBRT). the standard of care in medically operable patients. Unlike Methods: Between 2004 and 2012, 342 medically inoperable early- surgically resected patients, those treated with SBRT do not stage NSCLC patients treated with definitive SBRT were identified typically undergo pathologic characterization of the lymph in our institutional review board–approved prospective registry. All nodes. Despite lower rates of invasive mediastinal staging, patients were treated on a Novalis/BrainLAB system using ExacTrac retrospective SBRT series report either similar or lesser rates for image guidance. Kaplan–Meier analysis was performed with the of regional nodal failure compared with lobectomy patients. log-rank test used to detect differences between lesion size and nodal

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2014

There are no references for this article.